BRKR - Earnings call transcript Q1 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone, and welcome to the Bruker Corporation First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. And please note that today's event is being recorded. I would not like to turn the conference over to Miroslava Minkova. ahead. go Please

Miroslava Minkova

Bruker. would quarter I Miroslava welcome to Relations everyone and Good earnings like conference first for Investor of XXXX the is call. Bruker's I'm afternoon. head to My Minkova name

and Joining me on Officer. Gerald call are Financial Bruker's Chief CEO, our Interim Frank Herman, and Laukien, today's President

clicking be release release presentation presentation. slide The on of this the In earlier Relations during a addition earnings website. to earnings today's referencing today, be on downloaded Bruker's Investor by can issued hyperlink we conference the call, we'll PDF

During today's are be included highlighting financial information. website financial in non-GAAP non-GAAP on are posted our to call, we ir.bruker.com. measures and will Reconciliations at of release our our earnings GAAP

I show slide I on we Bruker's to Before begin, which would X. like statement, reference Safe Harbor

statements. to or based as conditions release not views outlook we on not information, do we'll Factors in XXXX. discussed actual the in should in new that August those reasons differences involve information company our materially may Form of in Also, or rely date of of second is release our forward-looking conference business and intend any results course financial SEC regarding in statements the statements forward-looking company's are earnings XX-K, filings. Consistent to, Therefore, practice, that events that on prior prior from our our but subsequent of as other projections this related or following of to The to to subsequent quarter the outlook results During today. and such such note statements well performance the XXXX limited uncertainties. be making financial described today's these as not you differ representing the as might our forward-looking the and XXXX. to call, our risks current cause future as today, include, May with future update events, X,

Gerald summary. in the for a call Frank financials of today's with begin will will the then first providing business We XXXX detail. quarter cover more

Bruker's call the Now, I'd to to turn over Frank CEO, Laukien. like

Frank H. Laukien

another Good you, on joining quarter, with our to afternoon, for or and year-over-year. you an profit organic earnings X.X%, the the business. basis, a expectations. On all Among the a Scientific growth organic strengthened improvement modestly by helped XX.X% for on Miroslava. of call. quarter, revenue business Bruker strong the increased in execution. thank is In Thank exceeding of with our recent Bruker's growth revenue quarter our today's everyone, off refresh healthy good markets, and highlights CALID start track significantly, revenue, portfolio, Bruker and operating us increased in first Instruments

NANO propelled Group strong another research markets. results had by quarter, solid industrial in Our

the Our to BioSpin had to due Group start year a timing. revenue NMR slower

increase budget. another we mostly Our meaningful end and by encouraged remain markets the are U.S. NIH healthy in

closely at quarter increase Looking [XX.X%] results $XXX.X our (sic) of more on X, year-over-year. million, an XXXX of slide first revenues we reported XX.XX%

where of $X.XX share year-over-year. increased the meaningful masked of $X.XX but will on scientific operating non-GAAP in by year-over-year. basis. On organic the grow growth instruments year-over-year, also XXXX. with XXXX earnings and In Foreign clinical was some below clinical X.X% primarily three XX a in X $XXX these first acceptances. net of food revenues margin compared provide which currency quarter exchange from income XX% of drag XXXX, further continued performance Bruker year-over-year of research intercompany XXXX gross basis, to organic our of contributed Please BEST at On operating groups decreases by revenue this call, margin the QX X organic QX and X.X% share impact to non-GAAP our year minus EPS and slow decreased applied turn as BEST, NMR phenomics QX result with BioSpin and million our minus systems constant strong compared QX revenues QX of well QX service our shipments modestly details X% our growth X.X%. on analysis. in by BSI segment now, headwinds eliminations. in the strong X.X% while acquisitions segment, XXXX on foreign in XXXX. was QX non-GAAP up levels, provide translation. and decreased reported QX slides research BioSpin, our XXXX had FX, of to Group all excluding year-over-year, an and a later $X.XX Within our improvements. Despite NMR per growth of operational system slightly bps a in to exchange for start GAAP quarter, XX In of X.X% a increased with I as $X.XX bps increased revenue non-GAAP and beverage highlights Gerald basis, of year-over-year. Aftermarket the had were to more markets per currency diluted the delayed

cell Just IDPs, announced proteins, even proteins, earlier globular for useful week, disease aggregates, on gigahertz-class and on on research. NMR structured will BioSpin membrane this on more high-field disordered make number intrinsically which products of research molecular new biology NMR or for a proteins and or

so NEO accelerate routine ramp or strongly, revenues NMR NMR customers. MHz our available preclinical with lines our preclinical imaging tests. MHz our We and architecture to NanoBay in good within PCI and and should were also AVANCE XXX micro-CT multi-receiver for in that our NEO XXX unique BioSpin, MRI up and product progress Also division's introduced recovering also continued is volume. preclinical a This now small-footprint novel console further

good target quarter primary two markets performance the results Turning posted science million. $XXX spectrometry. business We our growth they that within CALID, also microbiology refreshed are continues Daltonics CALID. from with high-single-digit our Biotyper global our the recently kits strong and execution healthy execution, exceptional results research business consumables had by of of II, life mass-spec the rollout of adoption believe continued markets. CALID products science and and academic products constant diagnostics, and research, and the pace. applied industrial rapid demand to and Within a life with increase mass yielding growth, ALPHA healthy at in diagnostics, had an currency outstanding like strong In with to Group, portfolio microbiology aided microbiology care to and revenue for in positive launched focused our growth Optics

support constant in research slide revenue markets. revenues exciting also growth now. turn detection lower QX CALID's but X of revenue In mid-single Finally, areas, uptick a with tools core $XXX industrial research industrial research, currency Please results some was million. can industrial lumpy Nano year-over-year. be and areas. Bruker digit strong reported Nano's to many growth reflected our

have organic new For example, advanced materials tools cells, cell we fuel into to two-dimensional novel like for materials, functional graphene, name and into few or technologies, solar a examples. research into into battery

by Our XXXX, industrial AXS revenues demand. in again fueled strong QX grew nicely

Semiconductor Nano also increased year-over-year. in revenues due delays. Analysis and shipment Surfaces flat Nano revenues QX Our some metrology to acceptance were and

with business by expect revenue revenue revenues As the we a some second in specifically continue second quarter new exciting with continued markets. conference workflow of starts the CE-IVD slide a a be disease-causing grew In which presence for reminder, infections introduced in you can demand decline X, to quarter, Madrid, in culture is semi ECCMID for an revenues that driven a available XX mark unusually microorganisms. we least, so-called basis or improved year-over-year assay, – the start, identification orders, as industrial Rapid In to Last now rapid Bologna BEST Europe and lumpy next faster BEST up to from microbiology. At on but sepsis. with MALDI a on to an positive was I quarter. Biotyper. Bruker like Sepsityper superconductor strong for microbial quarter a characterized in to would minutes and an by not in of the and high projected deliveries good the the XXXX. total, blood significant from the sizeable BEST quarter, in projects. solid workflow highlight year, the had our organic Biotyper workflow have allows for once bloodstream system to year diagnosis and about an of our at is of Despite on decline and level On now timing cost-effective the recent start Nano result Bologna for for with clinical XX Europe the and lights

MALDI testing MBT well. minutes possible As can We our cephalosporin kit dangerous for bloodstream kits a now Europe, the available kit and carbapenem STAR-Carba has two, as resistances: our Bologna Biotyper for combine less resistance; our in total an hundred positive MALDI a broad test of can resistance XX combined to of at per Biotyper sample new patients and reminder, micro-organism coverage, with customers. between species ID important also is and the the to price workflow information ID first, takes and coverage selected assays culture Biotyper XX and antibiotic and blood that two $XX identification assay STAR-Cepha, MBT from for physicians in lifesaving common in and potentially The and microbial gold-standard infections or the X,XXX resistance. this provide on for

one and about the culture, bloodstream sick Project initiatives, methods. savings of offering can we area. time-to-result result this more Bloodstream a this from for of for affordable and further introduction Accelerate Workflow, two-hour progress significant impact as for fast reminder, detection, have disease together expansion our cost and We very directly excited Infection as well in without six hospital diagnostics, our the the fast-detection very well product is are fungal Bologna new to with for as shortened and this high-growth, believe blood high-margin time us Microbiology these position patients, with the infection invasive

lean President BioSpin operations, am President. I Deputy of variety and XXXX Falko to as President. the joined to margin has expansion XXXX. Turning He BioSpin be served X, recently Under on growth for Falko of to Dr. R&D key responsible Group BioSpin Busse as and Executive focus BioSpin's our been leadership, also strategy of Group marketing slide pleased Vice most early in and announce Falko's since BioSpin has you functions, Interim he very will appointment Falko will GHz-class a in for Herman, Switzerland roll from took expected and mid-March. joined In our moment hear Financial out Gerald a positions. BioSpin's BioSpin as Germany XXXX our a including successive pharma, Mattacchione's Healthcare Chief Project and Officer departure major future Philips applied initiatives, markets Tony over as in where called after Bruker who initiative in years well from growth well operations. leadership as held as initiatives, aftermarket

We our our excellence fundamentally and organic operational first unchanged. good creating and to subsequent quarter, Gerald priorities interim Gerald portfolio remain he's in On healthy the ongoing excluding Accelerate expansion pleased to an by for and a we robust year-over-year call In progress our and Bruker's let have slide they summarize margin excellent look over X, you growth for as CFO our on CFO, our are delivered financial start. highlighted and We year-over-year me the continued key our underlying are that committed transformation, expansion I growth. Herman. to BSI Project short- customers and turn and segment, forward currency very EPS initiatives. On to strong headwinds, interim off remain margin as committed Bruker our note, We long-term to updating values as commitments, well on calls. summary, to via improvement shareholders our XXXX

Gerald N. Herman

join Frank. you, highlights and review pleased financial Bruker's on XX. you today starting Thank I'm slide to

year-over-year from QX basis basis non-GAAP On QX negative non-GAAP $XXX.X reported Bruker's declined per saw up versus which non-GAAP operating X.X%. of million points income compared release, share. underlying basis, foreign share, than XXXX. On in more to translation growth press a This revenue was trends GAAP offset increased prior-year $X.XX QX margin our in points included quarter, in in the QX EPS per to of QX, the to reported positive organic impact basis, EPS XX.X% currency XX of operational to which me, excuse quarter. saw our $X.XX We you $X.XX XX% XX.X%. we reflects a X%. increased operating XXX As the

cost and large Swiss a has in franc. Bruker base reminder, denominated euro a As

these With weakening also currencies, dollar's this a had outsized an relative impact the increase to our revenues, in currency-driven positive on our year-over-year but large costs.

had impact with currency basis million, a XXXX. XXXX, March on the $XX.X For neutral operating QX the XXXX of under working XXXX. increase million XX, of fund compared well resulted a an our quarter but We the shipment free XX% XXXX. to and we're $XX cash at approximately These growth, revenue and net as non-GAAP late-in-the-quarter dividend, revenue our our negative margins, QX roughly deterioration slight as bridge cash dollar of the with on the or impact QX net XXX revolver XX to year-over-year. The our of EPS. changes repayment foreign million revenue net down million position from of activity, cash product reflecting XXXX. the the balances, in to U.S. impact We in generated in cash acquisitions, in in with continued cash the of quarter in effects of first buybacks, our positive working higher QX Slide resulted X.X% We flow ratio. points weaker for slightly shows $XX.X capital use of decrease ended also from borrowings exited $XX.X capital quarter, revenue

growth perspective, gains businesses. was growth a a to a had and the digits. from year-over-year organic QX small mid-single mass-spec tailwind. to increased positive included of slow microbiology contribution NANO strong optics XXXX A an start with at which by translation CALID, year BEST growth high in and foreign revenue organic decline. BioSpin driven a X.X%. each X.X% From we addition the X.X%, modest of organic the organic the single-digit currency X.X% rate had acquisitions In revenue had growth

recognition. continue project in timing of intercompany measure, constant MRI excluding BEST QX of shipments, revenue BEST superconductors that which as currency in view as to a and underlying scheduled X.X% On we XXXX, increased customers we growth growth. revenue of the to better benefited indicator BEST BEST, deliveries from OEM revenue Regarding present BEST's

which double-digit growth significant revenue expected for product portfolio organic decline at We From and revenue research, conditions second stable continue an saw decline a we full-year organic in the with perspective, in end-market the academic group. year-over-year to NANO again momentum quarter. market BEST, expect a strong for propelled our industrial

full deliveries organic the We solutions European was being year-over-year mid-single with in a the business continue for digits to lumpy portfolio. to business year. in Geographically, biopharma our high an expect revenue strong our continue semi and a organic American see metrology but on single microbiology start. to North growth results grew we QX. our in increased remain basis, mass-spec in digits highlight our off in quarter. the biopharma, Semi good revenue

momentum acceptance digits low conditions QX delays APAC the and revenues were another we've BioSpin Pacific favorable results. some are in of single Slide growth XX Asia non-GAAP including with down organic customers. QX end-market been pleased that we with XXXX and Overall, quarter our shipment positive experiencing. shows

increase. orders our than margin up general was XX.X%, Our decrease the of were currency foreign points a and million QX volume weakening expense the also profit expense increases. by QX NANO impact merit XX% XX dollar. U.S. from major and XXXX more on foreign included basis commissions selling, and $XXX with increased movements revenue, driver administrative non-GAAP XXXX, and of was a this SG&A translation XXXX to Higher of higher Higher of QX gross the year-over-year. CALID operational due offset and of negative improvements groups within exchange

Central at driven initiatives, new remain shared in R&D and currency changes increased our spending. QX million, roughly addition primarily and finance G&A Projects in the some on announced expenses, service previously XX% Accelerated track. center by Europe, (XX:XX) of rates year-over-year, Our $XX including acquisitions foreign

of year-over-year our below the including was in favorable revolver and versus and interest net year, the a favorable exchange the the $X.X expense Looking million foreign line, transactions quarter. from pay-down other million impact of $X.X debt prior

our million our diluted in the share tax the QX about Weighted or which non-GAAP certain tax quarter the unfavorable tax This buybacks, X.X included first reflected effective option exercise items. were XX.X%, dilution. offset in year-over-year. XXXX partially lower first by XXXX, shares million, was down X% shares stock For effective rate XX.X% outstanding of XXX than average quarter XXXX, rate discrete

XX% driven tax Finally, cents XXXX, count. non-GAAP year-over-year share of higher by QX and EPS $X.XX revenue the XXXX increased from $X.XX in favorable QX rate and

XXXX. than to of customer This $XX in CapEx, free increase earlier Turning lower timing and higher year-over-year flow working in generated in bonus the we capital and QX $XX net described which an in slide XXXX, million advances, million approximately income, was by offset higher employee the increase slightly XX, reflected payments. partially QX cash in

the Our quarter same shipping higher cash QX quarter-end cycle increase lengthened of in by XXXX an versus due XXXX revenues in activity. slightly to conversion QX at end XXXX DSO, largely the in and driven

XXXX on for Turning XX, to guidance for revenue earnings our XXXX and outlook slide unchanged operating margin from expansion growth, our EPS are February non-GAAP call.

an reported For basis, including approximate and Bruker's XXXX expect we a organic X% contribution on foreign X% approximately from currency growth grow to translation. X% approximately revenue

BEST mentioned decline As projections organic net is these eliminations. business, earlier, an our in intercompany of in embedded

expand XXXX dollar. absorb between level in basis U.S. the XX non-GAAP basis expect margins and XXXX to compared operating of points full-year achieved headwind continue XX a to we the to exchange XX.X% to while weak points due We XX year-over-year foreign

projected Other Our slide, listed non-GAAP from rate including are to February full-year which tax XXXX our remain XX%. earnings rate unchanged at is guidance assumptions, assumptions call. foreign are our on exchange the

start the project bottom EPS representing a to our commitments. the start on look financial Bruker call between you to line, I'd summary, good on with compared again the turn to to In range $X.XX that, on and remain QX over deliver between XXXX. in conference August we like track XX% our and Thank growth to forward the continue to we and in you. full-year the had And XXXX. We call Q&A Miroslava to updating session. On to non-GAAP $X.XX, year XX%

Miroslava Minkova

the more analysts, please the William, questions call your up a one Thank and for accommodating our to interest you, to follow-up. limit open Q&A. we Gerald. of In would like of

Operator

Couillard with Brandon question. go be now will first today Jefferies. ahead question-and-answer our session. we begin your with the will questioner And And Please

Brandon Couillard

I sense quarter? in on you I the shipments, relatively were Frank, revenues debate said could give what's there? semiconductor view And us as on this but business, to were then, there's revenue? cycle, how percent us of some as And could in know your orders been, timing of afternoon. on how any the think, of you trended a we is orders? that how semi business just chance a remind big are good Hey, flat where you

Frank H. Laukien

Brandon. Yeah,

a So, so expect semiconductor QX expect both to up to be little still we were semi. QX for year orders in bit weak better but have aspects, the in also we metrology, in a much

from difference. back quarter, being happened, We a couple next few to a is big of have so makes that exactly systems the pushed systems what one which

our and is course Many market of read there. general I well, too into semi the much of data, So really still in the parts quite wouldn't particularly memory areas. debate out doing are

I this year, the year, last right for as fast think year. as to but we'll be looking well not we're still do probably semi all growing in

Brandon Couillard

a question on... Thanks. two-part And then for you

Frank H. Laukien

keep a so nice in X% mind driving about not sales, business. semi that It's Bruker. And of of it's really all is

Brandon Couillard

for question Okay, to then, good two-part secondly, And on BioSpin. you know. a

you this you Project quantify X-GHz to this rationalization, are on on might at at expected just point? there First, initiative think about And changed XXXX. footprint can NMR just hadn't respect this any or a you get come and your recently many been savings Is that's the talked to how along kind the door secondly, as to out together, year? be just And it in the able shipments background new outlook all with you then has going much? of

Frank H. Laukien

on planned France. and and Switzerland primarily some now time, in been it's some but in little in the pull a for XXXX, with the bit evolving investments Project that's to been we're and trigger further project, Germany being also So, something quite ready

$XX at had or recent conference our in normal First that's out I mentioned run of million point CapEx the rate. so CapEx, NMR that we a that in should all,

to going be years. over three obviously that's spread So,

We our German – It CapEx our also, not sites and to is larger of or that bolus there to spending. – leased various combine or save in it's that or have remaining a coming done to facilities it phases, it's our way, this a Overall, So, going including facilities, campus. were our – is going Swiss in normal have middle and but late sites project BioSpin is expected a to lean CapEx into facilities, particular reduce one. footprint is combine site two major XXXX around we by our third-party about number we of one expect have will less. when XX% NMR leased

productivity gains Now, there cost goes margin savings kind that, think of plan, our be efficiency annual and but expansion. and will that with some into normal I

cost identifiable productivity, expect restructurings. our not is factories terms savings, as to large footprint. as one-time In it to do affect a And contribute This process. multi-year a dramatic jobs, of of kind previous does it's number we reduce of not but it

will modern two our the lean project. a think our have our And so in the further new – operations for and we It and better it's flow a probably nice give three layout facilities on. for for decades next I growth, good need very applications, for with us much customers R&D really. it's to

last year. your So yes, question, that this X-GHz expect some the of gives have perspective. that you in Oh, revenue point to still will we presently we

to Of case to are gigahertz make XXXX, we begin and elsewhere, expect then if course year, hopefully reach committed our beyond. XXXX where that into up in in in we the they gigahertz-plus we and shipments needle milestones to get and begin next – – always technical move that could into pushed which

one the this year. we're of that making won't So that not That's story. a Accelerate investments Project the XXXX needle it's move

Brandon Couillard

good, thank you. Very

Operator

Deutsche Dan today Leonard our will be ahead. Bank. Please And go next questioner with

Dan Leonard

you. Thank

So Accelerate. another Project related project question,

you have the named now, about think top So had line I previously. the little Frank, but talked while don't accelerating you project a for

Does so naming guess a Anything And one, significance can secondly, question with share. you around project that new organizational new? create then formalizing Are associated wrong, can this? And momentum around initiatives? your any you is if growth project on correct for the initiatives? it there I'm the targets this I elaborate me of

Frank H. Laukien

high-margin that's – to to eventually Accelerate such that's external the a it's new mouthful. Yeah, calling our all the it six streets initiatives, world. a about been Project along, and so We've we've been because name always got of talking high-growth internally we – tired

to transformation externally. beginning also for portfolio the simply use name internal the we're So

a Project gigahertz that begun it still our roughly. of think NMR So Proteomics and some this the the of become or bigger obviously, within needle, number – improve that bio a of begin fundamentally to Accelerate, And them previously that middle when stride new profiles also have our Accelerate, significant growth something Project maturity about project. more many reach we sense, initiatives believe of that or the and hit I to it's margin we also will of and them the many to higher street part all in that the talk all reach begin yes, It's Accelerate their qualitatively Project not about, of And, rates. initiatives as revenue to and six over we've last fundamentally fledgling of years, or move a becomes they get move think as organic of and heard as like needle. that mass-spec you year, volume

strategy going along of our excellence, part and most it's, operational forward. fundamental with significant the So

with excellence. cost up and we'll small Of restructurings operational never on go projects; course give and lean they

size, that, items So, well that. with well or aftermarket, semiconductor, million above entirely move It $XXX momentum. is don't needle applied these just or modest new. above million, $XX it's some some microbiology in or is relatively nothing more are $XX million, however million; above having biopharma and $XX well that, like along they're the nanomaterials still of more And said still gets

very be While others, and year. mass, this NMR or small I still mentioned will bio gigahertz Proteomics

Dan Leonard

do my what you expect quickly at the And flow, your on How that Appreciate you increase. efforts Bruker underway comment for Okay. NIH you budget could follow-up make share? and hoping then money the question, capture are sure to that. to

Frank H. Laukien

because quickly. be money to Yeah. needs much now There's debate a lot so that, of spent there's that about

what You'd enough existing new existing and back money to from grant to we raising cycles. can't they the have program they're almost extent grant recipients with – because spend and they're anecdotally, increasing fast calling say, hear officers, grants some

that's little with the academic bit which of interacted So conference. feedback community I bit a CNC at the quite a from

get application NMRs, our ticket in likely imaging more until through or someone an a is the does little and are big grant something I become three very mostly optimistic, and a a overall, money only also think years it's academic States For mass United row, DOE at all good have still deliver in for and that But it's much but items, probably cycle especially in of good and us, existing or in perhaps deans story. some general. for universities get environment it bigger mean, nice more bit specs or a then increases. late funded. seen year, we XXXX cycle's spending obviously them, people I the the spend a optimistic. increases goes not And in go NIH, to more orders, customers others But

good quite for it's also think for Bruker. delay, the field. it's With I be some So going to good

Dan Leonard

for Thanks color. Okay. that

Operator

will today And with questioner Tycho go next our be Please Peterson JPMorgan. ahead.

Tycho W. Peterson

Hey, thanks.

is that acceptance. First, highlighting? a customer just the Frank, there else readiness is just Is and or shipment something delayed issue, there on BioSpin, NMR, you've commented this on worth

Frank H. Laukien

customer our magnets a at having of and It's probes same the and in internal time. readiness some ready, operations of mix everything

due make four doesn't at quarters a I there's of wouldn't operations customer on. and mix. I little row. just Part a a that, it quarter in a certainly a us So should into of of trend BioSpin. a going it think sites. look quarters due lot especially at and of of part to it's bit our two anything part row, to all own is read in or is but don't three a

preclinical the parts I phenomics in well QX. other the the and we'll of And of also food up remaining done research So analysis very do BioSpin, and some very, imaging, clinical think that the in really aftermarket, delightfully quarters. and for catch have well systems

slow bit start, we'll a a BioSpin, think I be okay of we So with had but yep.

Tycho W. Peterson

relative other there? out the help in us I Okay. are And new workflow think MALDI the of then guess platform versus ID/AST you competitively that Biotyper some can and importance how about think about guess I you the,

Frank H. Laukien

the that to – was what you description other what the Compared Tycho? platforms, used,

Tycho W. Peterson

Other that platforms susceptibility will do and testing? antibody identification

Frank H. Laukien

Yeah.

Tycho W. Peterson

importantly, market for opportunity launch change you more guys? the does But how the

Frank H. Laukien

leverage yet. can there's year price-sensitive more have so quite it's the of of Right the also – We so so, this we important. testbed I don't think us. but FDA now outside a It's some have in market, and of course and at very market Europe. think important. certainly we it's work be no, for come European maybe we done, or a that end CE-IVD next to That Yeah, is very, is very good Europe, but of always

days of With First after dogma resistance and it hospital make data, to ID, in a unless blood as don't making people are ICUs a should. so people fast or these just have the old be they was decisions, clearly all, used and an they hour settings It's within or decisions that remarkable. treatment positive it AST changed. culture, really has

Some versa. antibiotics certain vice to are some and things – not applicable bugs, clearly

fast that save or a resolve, ID very could Biotyper, the So altogether a day a very the the some and it or helps, or importantly, genomic having in the then already subtle other mechanisms but looking of other for because resistances to just three. MALDI minutes tests, again, two which be cost-effective not way and is test of having or getting functional way, so; – by – major very lead time on there to functional resistance fast and XX pretty important can by using tests, genes

other into deployment Let's effective to if is cost this could it a a small-scale for deployment two. say really about And think wants will find think we only effective. nobody to publications. specialized These is go I part large-scale And it's, the few rather they're where tests day widespread cost I acceptance effectiveness. typically than talk think – or that cost

nice The is Obviously out. for to we that placements. systems this X,XXX with we we thing to a start Europe. and need perspective take is have those Biotypers Biotypers years that deal. So think workflows don't worldwide, can Europe really X,XXX so these about be start the in start rolled five have tomorrow. to, is three wish really big that systems If to with they could they People that in

is the deal. is ID. another This of introduction. a with a for this strategic So, is S-curve Biotyper S-curve, This big the

Tycho W. Peterson

overall? Can just Japan, there on Okay. improvement one. And any you one then of comment last signs there is

Frank H. Laukien

a up was we've It a in QX bit in a lot it tick orders. had weaker revenue better was previously. in bookings because has Japan little been on –

back in maybe the orders of actually, industrial but up, little a research. to were exception Japan weaker, bit were looking revenues So went with

I much one would too not I And quarter. own and a heed again, picture, mixed should So, read say. into advice my

two for not... quarters. Let's it's But, watch or this three

Tycho W. Peterson

Okay.

Frank H. Laukien

– not not Japan clear last more year, fall, last say have any – late I'd last that might that's got I It's a discernible optimistic than trend, trend. that there's

Tycho W. Peterson

Okay. Thank you.

Operator

be the Meehan Please ahead. next Jack will questioner And Barclays. go with today

Jack Meehan

Hi. Thank you. afternoon. Good

you had about easy in the within about comp dig through of there, results rest CALID, little just the to what Maybe I think the wanted Daltonics results and on you're year? at just good. an think grows So, a talk how the look but business talk – bit seeing you

Frank H. Laukien

are and fast microbiology, growing basis, large fast franchise and it's carry So very but is they're for margins. two, have Bruker. consumables like of there. not But year aftermarket that yet, there not we installed the that – they microbiology or anymore. growing be probably that been we're the but that time aftermarket a good not a revenue. pace, that and particular primarily at probably quite good, growing, have we're will from point, It's We're part no wonderful far in been To but from lower business it's still of a a at That's our instruments half really base so that problems anymore. the a first within course,

discussed mass really before life just with this Tycho doing introductions that's quite these And healthy. really very that that were segment And delightfully, So, quite was over well, spectrometry well. I are that's science business time. the at product significant that

with the portfolio with and mass applied in our sorts timsTOF spectrometry we MALDI magnetic importantly did systems, systems, markets okay rapifleX well applications. QTOF of doing new systems, well. new update also the with systems, in also think as markets, the the life resonance research academic science And other and but I in pharma all

So as business it's well, been somewhat this by were and QX. really broad-based may encouraged that its get we footing

Jack Meehan

would be to get to update it – deployment. just great an then capital related thoughts on And Great. your

buyback given M&A increased, do front? are on share Just seeing has willingness the to and performance, you what more your the

Gerald N. Herman

a that on Hi, authorization the share million That's on about have might I'll existing that. board. authorization, from you it's Gerald. remaining an two-year question. we repurchase I still question, guess know if $XX just the take

capital of bit the business. a on or quite pause core we to perspective, should But to like of repurchases a on have front we us to the restart still that. deployment opportunities depending we time from in support that, do So act choose continue flexibility we to the share see that

Jack Meehan

you. Thank

Gerald N. Herman

Sure.

Operator

Sung Nam was And our go next be BTIG. will Ji questioner today ahead. Please

Sung Ji Nam

questions. the taking for thanks Hi,

expected particularly think on – normalize some congrats there maybe low-field and of mix if NMR Frank, the you year. correctly also was to on business, recall last this your for mix I on I to BioSpin, correctly, due I And margins of remember I year if that think quarter. NMR, higher First headwind product if all,

of in the mix? seeing to pipeline just kind that terms are more order that of you so product expect based to now, you be year do this continue And on normalized

Frank H. Laukien

Yeah.

product I a mix. had think favorable XXXX particularly

I'd only I efforts improve little operational rebound would there are I in expect product So remarkable quick but yet. don't quarter. it's from ongoing to to early a year, too mix. say it's not BioSpin, a say anything margins the that a because there's at think But

Sung Ji Nam

if Okay. market to well Thank overall side, some share do mass-spec end-market market there obviously positive taking attributable I you that the – or saw quarter. kind this share some then, growth, well? that. are Thank on was some growth you. life you science think strong be that – of as you seeing wondering for you end-market And as could

Frank H. Laukien

spectrometry? the mass life In science

Sung Ji Nam

Yes.

Frank H. Laukien

Yes.

people trapped a spectrometry a are it. specs, proteomics. doing It's Q-TOFs rather we're also, and our of lot proteomics, our mass rapifleX, at mobility capability. are just been think intriguing and unique well formidable It's on But capability, at and unique it still but and days we're our that in well. taking look research a MALDI-TOFs targeting ion and hasn't I also other with available early particularly high-end capability TIMS doing

it's we'll we're I our with somewhat those this do – spectrometry So that think year. are product markets, quarter, I well and healthy but refreshed think only mass a optimistic we're line in science life

Sung Ji Nam

you. Thank Great.

Operator

And go be Murphy Amanda William questioner Please with will our next ahead. today Blair.

Max Smock

specifically, bit for upside the that know opportunity played of has within growth end Max I wondering, here? Amanda. comment we in some based And around is to This in the first guidance. through just just the that quarter, How And you remain results the on made on talked where I the I'm on mostly they a said markets, prior little about wanted to follow then quarter up a Hi. healthy. China. you that moderation most you out optimistic quarter for feel for maybe about

Frank H. Laukien

I XXXX, don't a well, but it in necessarily, more affect think always rates a growth obviously at in rate. phase look normalized. XXXX, have growth temporarily Yeah, In recovery settle guidance was it would in drop; Europe become if I in the trends, expect to we you steep and higher

a NMR were we maybe call little more going also delays moderate I normalized things, normalized, you level quarter. years for – single right? But European and had of but grow noise now they're bit double-digit a That's we China, couple become growth couple rates forever. to think high after BioSpin digits So pretty happening, think as couple a to there and of just and and the in as them, so the still going of there, can we at would be isn't to Europe anyway, expected well. good healthy And growth happen, not for a that's

this revenue, in to maybe be – think surprised reform, wouldn't also we'll for not there year may but and markets I continued I U.S., So upside, academic have U.S. to the but in – market, including And up. if general U.S. observe terms after pick necessarily us tax of as that.

further, our but U.S. the that remains if be that hopeful anything, somewhat and to maybe that will maybe then I'm may, accelerate So affect XXXX, seen.

Max Smock

And quarter, just mentioned then and moving into a how base I much how unrelated so, existing you. trying of bit is Got and your – you get on an selling it. note, in the how a AVANCE if of sense I'm contributed, in then Yeah, if that of know to that's terms helpful. penetrated NMR and forward. Thank much AVANCE

Frank H. Laukien

clarification, So, that years. multiple we've for over XX generations using just been in for AVANCE,

which NEO, new... of So, sort the mean the obviously you is AVANCE

Max Smock

Yes.

Frank H. Laukien

ever that now solids primarily high ...architecture, and very nicely, the week at if units We've there's NanoBay. Yeah, installed that you for no, We've shipping QX. conference, more the customers. that really since fourth generation shipping And step a along with we've on. NMR NEO AVANCE research been AVANCE, of XXX the now and taken this coming the about ENC like. fitting-below-the-bench earlier second so with field that's demanding applications, been compact,

And works customers. a but it Sorry, NMR for is it's that rather for and XXX-MHz really XXX-MHz customers. routine name, long

platform, fundamentally new a quite experiments NEO new conference is that, it's fact, shown of multi-receive as incremental older really the generational really enabling a just not a this at being for this ramp-up you the So, actually architecture, experiments anymore. on couldn't that of run and with new new change, architecture bit a were which improvements matter spectrometers

upgrade vendors, nowhere upgrade we orders, seen uptick upgrade year. Obviously business, business, of years So business is near other upgrade there some console and and or have we're penetrated console in us between there. already – also last

and pick all the We frequency from we to the ultra-high-field organic anything, chemistry full range way expect as more now and cover up continue, momentum if applications to that routine systems.

well. So really that's going

Max Smock

Thanks. Got Yeah. it.

Operator

ahead. Cowen. questioner go And Schenkel will next Doug our with Please today be

Unknown Speaker

for on (XX:XX) Hi, good just on today. my is margin. afternoon. first operating Doug actually is This question Chris And

I through benefit margin operating the key implies restructuring declined that expansion are mostly the QX what to the QX guidance think is initiatives since year? do QX, year? (XX:XX) more remind driven to later margins have you expansion for us Is much or the Could material margins year-over-year. expected incremental of in balance margin this you just it some are drivers volume

Gerald N. Herman

volume into and have those. with of mix. did actually, We Well, BSI number significant the together revenue put it's XXXX, outlook for growth a

As well, with together we leverage, Frank's the Project Accelerate expect operating mentioned. that already initiative

factors. But operational say those also initiatives. be a of I'd excellence number continuing main have We the would

Unknown Speaker

it. Got Okay.

Frank H. Laukien

operational restructuring we're major European every center at about mean, I will excellence two We of take when initiative. the acceleration to It operating operational our three cost and the had year had The multiyear some just – Project from and restructurings. organic taking excellence expansion over Accelerate last services every BioSpin point. that four we not further Yeah, lean the at Project margin shared those of XXXX no this course time, a out – are comes one that It's in moving years the Central Europe comes like significant profile initiatives. year. more incremental gradually. from – or steps or different of from we margin is that growth,

Unknown Speaker

Okay. class, to isolated And product then you APAC just performance? for APAC updated just on a by the detail growth could for and just BioSpin more and or expectations year? you for more the my segment was provide was bit decline follow-up Specifically, broad-based it provide can question, maybe

Frank H. Laukien

our that in to not We're updating view go granularity. don't we of general. level Yeah,

mean us, that that is much. quarter doesn't all a always issue just For the

and down, average might be China, – slow, sluggish in over then three of quarters. one, I have don't quarter and Some our one and great mean, you quarters divisions a it China quarter two the a we next slowing yeah, that quite or and double-digit – have, And, pace our expansion the to Last that year that opinion see compounded maybe China, we've we we with alerted everybody impression. in our seriously at we think that. information. in two that's is by we look stuff delays of noise than look by that that geography look you quarter, But see China because in I same, really some and quarter – the one the any would that, then you more to I quarters, will in given do at that three if really type I I product that's – more encourage or after noise at it QX. slice BioSpin and had

not That's after for teens So not to three had the term will I we than any us a high I or at don't basis. on trends mid-teens clear surprise or in assumed the longer look probably so, two sustainable trends that also China other quarters. that. see a at – trend, grow

Unknown Speaker

questions. taking my great. for Thanks Okay,

Operator

Cleveland question Please next Steve our with Research be today Company. And will ahead. Willoughby go

Steve Barr Willoughby

Hi, good evening.

quick Frank. things two you, Just for

the quarter. you overall X% to for secondly, was the First, could company here put organic first quarter, high And compared how comment in digit last then growth believe single up you the just growth had I this order on orders you year?

left unchanged X%. year, is is which guidance, the Your for

some areas a had quarter. delays shipment of couple the here in You in

as had the what X% gets of So, you to kind the compared worse just first the here in wondering year quarter? growth goes on,

Frank H. Laukien

just We anything I mean, – worse. guidance that our Yeah, gets after we don't quarter. one I'm touch not saying just

is is and a QX away. QX us, still bit so important, For

pleased quarter. we're right So comfortable We're our first our with with now. guidance

you was contributor BEST a high still QX, that, really growth QX of a exceptionally in and had in revenue we recall, BEST, If highlighted XXXX.

QX an So decline specifically. double-digit have BEST will in organic

to the So you color some but model that's how not more you as that probably news us, quarters flow the year. may give

think to – growth order your mid-single I So digits. the in with question, that, first again our Steve, organic was BSI

quarter, that, think decline it'll on have yes, we're QX. in even a much we were an of we expect steep dip organic BEST bit it the a organically organically still BEST track. – XX% that So, top we though in and of year, on QX. And, the full That's steady grew to how the XX% for for of noise BSI more pretty a being really growth with then But we're mid-single at the we segment, business, year evolves little this and – our lumpy, we're is at it's But with And pleased. with long always QX But, big confusing. little for comfortable BSI. it's year. it's I think best so guidance. times at yeah, year, this obviously I pleased QX appropriate us, in That's a the lead We're organic have point. for order and know digit guidance the point in the which with

Steve Barr Willoughby

Thank you much, very Frank.

Operator

Donnelly And be next go ahead. will Patrick Sachs. questioner with our Goldman Please today

Patrick Donnelly

data, one in Frank, Can in on talk specifically bit quarter? that April. region even and PMI through trends Great, a soft got UK the you was weaker the Europe. March and you maybe just this saw thanks.

seen course government flow the two curious, you've I'm last that maybe region that about over in volatility how the of funding given the data you've in the that, and you're the how So years, in the region macro seen perspective feeling to past?

Frank H. Laukien

isn't longer good sort and I my term grow very I single was I that just Europe I apologize, on digits. sustainable QX. in us the in mean, so basis comment a high Europe going to probably, repeat of Yeah, think for

very into nice it back us, So in for order Europe The had We this after we're in this growth kind a dip recovery. and significant growth was because pendulum a translate of year will swinging taking that thought rates into rates, account. high part revenue XXXX.

Europe sign more was it we So healthy single recovery demand but will level, high We a think a nothing than was a level that at think XXXX. that. to normalize digit non-sustainable really it orders of at after probably there's and

on So Europe. those you optimistic observations. with know, But we're

Patrick Donnelly

another on that's the then And revenue, side. been quarter. strong specifically know for aftermarket helpful. service you, That's a on I focus maybe the one

where feeling is that in growth story, wondering how going that sustainable and rate a are trending, just in part rate about how forward? the we attach So you're

Frank H. Laukien

very long that much gross that one leave aftermarket margins, initiatives. Gerald. into although can that? Quarter-by-quarter, I'll good Again consumables Miroslava, is a Maybe comment think to is too and particularly growth something one lower with on It you our has I operating we also read quarter? mean, term, margins. caveat, of don't

Miroslava Minkova

the slightly it quite are Yeah. On overall doing the The grew this quarter. what well aftermarket, quarter. Patrick, and below average it filings a was that number a just – that an on this that quarterly accessories accessories was in parts, organic consumables But and our software and – basis, was a the drag corporate lot see of some was in services, you actually part is includes and bit disclosures a faster.

see growing component but that number. another growth there in that the So fast, will is you are initiatives included

Patrick Donnelly

you. Thank

Operator

America. today ahead. will Please questioner next Derik be our go And of Bank with DeBruin

Michael Ryskin

wanted that of having events out the – spread indication bit And year? last with – that Thanks elsewhere, lumpiness of the just thanks. the up some on and sense as on said some CALID. a XGHz far follow you It's for are Nano to Any imminent NMR Oh, squeezing we I was shipments mid-XXXX. of the again, are a get you and it Mike mixture customer I – was the as questions or little it to a a the earlier last talked shipments for are course of these us about Ryskin couple then are orders delays. more talked, Derik. these about in. are on over wanted where goes,

sense Just can pretty XQ, flat the XXXX, a you you're – looking for of the trying to for get if the as bulk BSI at over a QX, trying for, comps sense far tell? as was pacing, to QX get

Frank H. Laukien

of would given – Obviously year. so memorable, difference. Bruker get it's tends in the again, QX. it up That it spread be remainder this it's or side, over part into one to QX with we no, still in XXXX once happen year, be it's going quarter, sustainable not gets one in year. if obviously in for quarters. one we while if and hopefully NMR in the out it's in business, this that which but would the goes one's XXXX, or our overall catch over typically. The Yeah, a more it it'll if X-GHz, plan, – be make not Gigahertz crucial is – $XX BioSpin revenue, it, That And it's that multiple below doesn't or But some million, any revenue. in

Michael Ryskin

follow-up. quick And a Thanks. then it. Got

the was how give of us mentioned that pay delta and course sort each other million $X.X you revolver You income, that model? the the a that the was Can that our delta, the how of over meaningful interest break because contributed, down, of part was the progress there one transactions. was – of to should sense on down, much year-over-year; that part for that a year, FX pretty

Gerald N. Herman

it's we're foreign It's but the that case. principally foreign prepared exchange give impact not principally base in on had to numbers, that exchange, but

Michael Ryskin

Thanks. Okay.

Gerald N. Herman

Sure.

Operator

Puneet go next Leerink be questioner Souda Please will our with Partners. And today ahead.

Puneet Souda

for Yeah, – thanks Frank, for hi, taking hi, Thanks Frank. my question.

that XXXMHz, were with those XXXMHz magnets, around largely this issues. to NMR timing the timing, part Are associated lower – around just the more wanted or So the anything just XXXMHz, clarify. I briefly the types XGHz? in or on of is the

Frank H. Laukien

And more nothing think has but XGHz. higher nothing field, recollection is so more with to XXXGHzs. do mids to routine mid higher XGHz. I field, ultra-high not It do the to field. my to that it's There's not with But,

Puneet Souda

further? BEST. then you. you further you, that Burkhard obviously to any team be the describe team and in you the now Thank just businesses think before, thoughts recent things it. evolve How other would of appointments, makeup Got had in you. the Any where just to helpful. Thank overall, in even order say, compared needs Falko would to grow And what and BioSpin Okay.

Frank H. Laukien

Yeah.

up about publicly-traded further by company. bench a within strength left had CEO in, recall, a strong team we to have think our grooming year like step and with training, someone stepped have I after some has become René of very I to just a mean, really and team. we Lenggenhager, if terrific stepped have you that and we impressed just some up. how individuals a I'm Falko

think we have a time. we this we're really think I that for management very meeting, a in I just point here – So, team had quarterly team and in team leadership at strong

Puneet Souda

one then And just one last quickly.

U.S., In are Europe. terms going most of the XGHz, NMR in larger the in orders of these

strength, O-U.S.? philanthropic expectations Thank in order is that I U.S. NIH U.S. largely still field XGHz right think there's in have But potential you to for it be or for at one from around or all you. do going

Frank H. Laukien

we O-U.S. visibility, have it's From what

Israel, is all a – – indeed, presently Canada, encouraging. organization, yet. in well, – from philanthropic research – research I little be that there program. it's a all fully not At premier least, think bit U.S. would visible research O-U.S. is was don't the premium NIH a concerted order in there that almost Europe, In – actually medical bit a a little U.S., that's there So, a also some that was

it it some in funding. state, There to but clearly in some Europe. something, organized think as in and philanthropic, is I together do been NMR endowment has So more consortia be community the some individual or NIH, it interest the U.S. as stitching in maybe some is might some not universities

discrepancy very bigger does and with bigger, one and compelling some becoming is However, there's gigahertz-type NMR. the science

individual I question in I U.S. X-Y-Z I But says yeah, don't it's, So it's we're seen see the piece the sources. that you've from money now like funding combine But assume try a to organized in other investigators that. the what then where of yeah, time. That's are that NIH to would NIH right an and to investing in a often U.S. get they open of think initiative with

But, O-U.S. this state. point, healthier present it's yeah, the much at I that's surprisingly. So know

Puneet Souda

you Bye. very Thanks, Frank. Okay. much. Thank

Operator

remarks. And our session. the this closing conference Minkova would to any turn conclude over like to I now Miroslava will back question-and-answer for

Miroslava Minkova

you for Thank William. you, this us Thank evening. joining

our will Thank conferences visit New you, at York, Healthcare Deutsche quarter, meet us William have and the in During second headquarters you Conference Growth in Conference Boston, Bruker Massachusetts. to us Bank in in the or Jeffries Blair Billerica, a the Chicago. these and good at the in participate invite Stock Healthcare We Conference evening.

Operator

for concluded. now today's has conference The Thank you presentation. attending

You may now disconnect your lines.

Bruker (BRKR) 3 May 182018 Q1 Earnings call transcript